Lucid Capital initiated coverage of MeiraGTx (MGTX) with a Buy rating and $50 price target MeiraGTx is developing next-generation, genetic medicines to potentially unlock cures in chronic diseases, the analyst tells investors in a research note. The firm says the company is “providing a toolbox to pharma.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGTX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue